Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, UCB Pharmaceuticals, Pfizer, Eli Lilly and Co. and Forest Laboratories

For Immediate Release

Chicago, IL – August 24, 2010 – Zacks.com Analyst Blog features: Jazz Pharmaceuticals Inc. (JAZZ - Snapshot Report), UCB Pharmaceuticals (UCBJF), Pfizer Inc. (PFE - Analyst Report), Eli Lilly and Co. (LLY - Analyst Report) and Forest Laboratories Inc. (FRX - Analyst Report).

Here are highlights from Monday’s Analyst Blog:

Jazz Pharma Faces Setback

Jazz Pharmaceuticals Inc. (JAZZ - Snapshot Report) recently announced that the US Food and Drug Administration’s (FDA) joint advisory committee voted against the approval of the company’s fibromyalgia treatment, JZP-6. The agency’s Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 20-2 against the drug, saying that the risks of JZP-6 outweighed its benefits.

The FDA advisory committee also asked Jazz Pharma to review the Risk Evaluation Mitigation Strategy for JZP-6. Although the agency is not required to do so, it usually follows the advice of its advisory panels. Given the negative feedback from the FDA’s advisory committees, we believe the FDA will most likely delay approval of the product. A response from the agency is due by October 11. Jazz Pharma intends to work closely with the FDA during the review process.

The company has an agreement with UCB Pharmaceuticals (UCBJF) under which UCB Pharma has the right to market JZP-6 as a fibromyalgia treatment in 54 countries outside the United States.

We currently have a Neutral recommendation on Jazz Pharma, which is supported by a Zacks #3 Rank (short-term Hold rating). Jazz Pharma has two products on the market, Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy and Luvox CR for the treatment of obsessive compulsive disorder and social anxiety disorder. Xyrem, the sales of which have been accelerating since the last few quarter, is the main revenue generator for Jazz Pharma with fiscal 2009 sales of $31.6 million, accounting for 83% of total revenue.

The company also has several other candidates in its pipeline, which are being developed for indications as diverse as restless leg syndrome, seizures, epilepsy and bipolar disorder. However, we note that these candidates are still several years away from commercialization.

A delay in the approval of JZP-6 would be a disappointment for the company and even if the drug is approved, we believe it will face stiff competition from players such as Pfizer Inc.'s (PFE - Analyst Report) Lyrica, Eli Lilly and Co.'s (LLY - Analyst Report) Cymbalta and Forest Laboratories Inc.'s (FRX - Analyst Report) Savella, for the treatment of fibromyalgia.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

Read the full analyst report on JAZZ

Read the full analyst report on VCBJF

Read the full analyst report on PFE

Read the full analyst report on LLY

Read the full analyst report on FRX